Agilent Technologies and Accelrys announce software licensing agreement and technology alliance

14-Aug-2002

PALO ALTO, Calif., Aug. 13, 2002 - Agilent Technologies Inc. and Accelrys Inc., a wholly owned subsidiary of Pharmacopeia Inc., today announced a software licensing agreement and technology alliance expected to result in software to assist pharmaceutical and biotech professionals in the development of more effective drugs.

Under the terms of the agreement, Agilent will license the use of Accelrys' Viewer ActiveX Control for 3D visualization of molecular structures. The Viewer ActiveX Control will be integrated into the recently released Agilent Synapsia Informatics Workbench, and will enable scientists and technicians in the pharmaceutical and biotech industry to visualize and share molecular information in a clear and consistent manner across the pharmaceutical value chain. It is expected to further enhance the collaborative knowledge synthesizing capability of Agilent's Informatics software, and therefore help accelerate decision-making in the development of more effective drugs.

Other news from the department research and development

These products might interest you

OMNIS-Software

OMNIS-Software by Metrohm

Efficient Lab Workflows Through Intelligent Data Management

Central Data Management with an Intuitive User Interface for the Highest Compliance Standards

laboratory data managment software
Limsophy

Limsophy by AAC Infotray

Optimise your laboratory processes with Limsophy LIMS

Seamless integration and process optimisation in laboratory data management

laboratory information management systems
LAUDA.LIVE

LAUDA.LIVE by LAUDA

LAUDA.LIVE - The digital platform for your device management

Comprehensive fleet management options for every LAUDA device - with and without IoT connectivity

laboratory software
ERP-Software GUS-OS Suite

ERP-Software GUS-OS Suite by GUS

Holistic ERP solution for companies in the process industry

Integrate all departments for seamless collaboration

software
Loading...

Most read news

More news from our other portals